Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 5:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 4,980 matching trials from the live ClinicalTrials.gov search.

Filters: San Diego, California Clear all

Conditions: Chronic Lymphocytic Leukemia
Interventions: Dasatinib and Rituximab; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Pneumonia
Interventions: Diagnostic test on urine samples; Diagnostic Test
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years and older
Enrollment: 12,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 40
States / cities: El Centro, California • Fontana, California • Los Angeles, California + 25 more

Conditions: Ischemic Stroke, Intracerebral Hemorrhage, Subarachnoid Hemorrhage, Dementia, Vascular, Mild Cognitive Impairment, Vascular Cognitive Impairment
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 8,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 31
States / cities: Phoenix, Arizona • Los Angeles, California • San Diego, California + 24 more

Conditions: Patients With Severe Chronic Pain
Interventions: Ziconotide; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 43
States / cities: Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 37 more

Conditions: Obesity
Interventions: VeSTAL; Device
Lead sponsor: Neurovalens Ltd.; Industry
Eligibility: 22 Years to 80 Years
Enrollment: 241 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: La Jolla, California • Austin, Texas

Conditions: Atrial Fibrillation, Arrhythmias, Cardiac
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 21 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: San Diego, California

Conditions: Age Related Macular Degeneration (AMD)
Interventions: GT005; Genetic
Lead sponsor: Gyroscope Therapeutics Limited; Industry
Eligibility: 55 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 22
States / cities: Poway, California • Durango, Colorado • Gainesville, Florida + 18 more

Conditions: Opioid Use Disorder, Addiction, Opioid
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: Not listed
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2028
U.S. locations: 8
States / cities: San Diego, California • Denver, Colorado • Boston, Massachusetts + 5 more

Conditions: Colorectal Cancer
Interventions: capecitabine, oxaliplatin, resection, radiation therapy, FOLFOX; Drug · Procedure · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 119
States / cities: Mobile, Alabama • Auburn, California • Cameron Park, California + 94 more

Conditions: Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
Interventions: NKTR-255, Cetuximab; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 6
States / cities: San Diego, California • San Francisco, California • Minneapolis, Minnesota + 3 more

Conditions: Triple Negative Breast Cancer, PD-L1 Positive
Interventions: Sacituzumab Govitecan-hziy, Pembrolizumab, Paclitaxel, nab-Paclitaxel, Gemcitabine, Carboplatin; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 247
States / cities: Anchorage, Alaska • Tucson, Arizona • Hot Springs, Arkansas + 175 more

Conditions: Pulmonary Function
Interventions: Not listed
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 6,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2029
U.S. locations: 6
States / cities: San Diego, California • Decatur, Georgia • West Roxbury, Massachusetts + 3 more

Conditions: Rheumatoid Arthritis
Interventions: BMS-945429 Placebo, BMS-945429, Methotrexate, Methotrexate Placebo, Adalimumab Placebo, Adalimumab; Drug · Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 13
States / cities: Peoria, Arizona • San Diego, California • Trumbull, Connecticut + 10 more

Conditions: Uncontrolled Hypertension
Interventions: Renal denervation (Symplicity Catheter System), Renal angiogram; Device · Diagnostic Test
Lead sponsor: Medtronic Vascular; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 79
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 61 more

Conditions: Fabry Disease
Interventions: Not listed
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: Not listed
Enrollment: 9,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2034
U.S. locations: 91
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 70 more

Conditions: Hyperlipidemia
Interventions: Bococizumab (PF-04950615;RN316), Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 58
States / cities: Birmingham, Alabama • Tucson, Arizona • Encinitas, California + 45 more

Conditions: Depressive Disorder, Major
Interventions: Esketamine, Placebo, Standard of Care; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 18
States / cities: San Diego, California • Farmington, Connecticut • Miami, Florida + 14 more

Conditions: Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
Interventions: TPN-101, 400 mg/day, Placebo; Drug
Lead sponsor: Transposon Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: La Jolla, California • Orange, California • San Francisco, California + 5 more

Conditions: Nonalcoholic Fatty Liver Disease, HIV
Interventions: Aramchol, Placebo; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: San Diego, California

Conditions: Mild Traumatic Brain Injury, Posttraumatic Stress Disorder
Interventions: CCT+MBLT, CCT+ION; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: San Diego, California • Portland, Oregon

Conditions: Bipolar Depression
Interventions: lurasidone + (lithium or divalproex), Placebo + (lithium or divalproex); Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 27
States / cities: Little Rock, Arkansas • Anaheim, California • Chino, California + 21 more

Conditions: Metastatic Colorectal Cancer, CRC, KRAS/NRAS Mutation
Interventions: Onvansertib, FOLFIRI, Bevacizumab, FOLFOX; Drug
Lead sponsor: Cardiff Oncology; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 41
States / cities: Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 35 more

Conditions: Lymphoblastic Leukemia
Interventions: Dexamethasone, Mitoxantrone, PEG asparaginase, Bortezomib, Vorinostat, Mercaptopurine, Methotrexate, Blinatumomab, Ziftomenib; Drug
Lead sponsor: Tanja Andrea Gruber; Other
Eligibility: Up to 1 Year
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 17
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 14 more

Search by objective public record fields.

A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia

A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting

Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY

Patient Registry of Intrathecal Ziconotide Management(PRIZM)

Vestibular Stimulation to Trigger Adipose Loss (VeSTAL) Clinical Trial

The Maintenance of Human Atrial Fibrillation

ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study

Leveraging Artificial Intelligence and Multi-Omics Data to Predict Opioid Addiction

Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis

Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Service and Health Among Deployed Veterans

Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate

SYMPLICITY HTN-3 Renal Denervation in Patients With Uncontrolled Hypertension

Fabry Disease Registry & Pregnancy Sub-registry

Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events

54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide

A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy

Improving Cognitive Rehabilitation Outcomes

Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II